生殖系RUNX1突变患者血小板转录组分析
研究对3例携带杂合RUNX1突变的长期血小板减少患者进行血小板转录组分析,发现p.Gln268∗和p.Thr196Ala变异患者存在RUNX1靶基因异常表达,而p.Asn159Ser变异患者无此表现;血小板表型、家族共分离和转录组分析支持前两者致病性,不支持后者。
要点
- 血小板转录组可区分致病性与非致病性RUNX1变异。
- p.Gln268∗和p.Thr196Ala变异患者显示RUNX1靶基因异常表达。
- p.Asn159Ser变异未显示RUNX1靶基因异常表达,不支持其致病性。
核心结论
- 血小板表型、家族共分离和血小板转录组学支持RUNX1变异p.Gln268∗和p.Thr196Ala的致病性,但不支持p.Asn159Ser。
- 本研究进一步证明血小板RNA分析可能有助于对致病性RUNX1变异进行分类并识别新的RUNX1靶点。
研究设计与样本
- 纳入3例携带杂合RUNX1变异的无亲缘关系长期血小板减少患者:P1为新发c.802C>T[p.Gln268∗]且近期发生骨髓增生异常综合征;P2为c.586A>G[p.Thr196Ala],该变异在家族中与血小板减少和髓系肿瘤共分离;P3为c.476A>G[p.Asn159Ser],该变异未与血小板减少或肿瘤共分离。
- 进行基线血小板评估,制备超纯血小板用于血小板转录组分析。
主要发现
- 在P1和P2中,转录组分析证实被认定为RUNX1靶点的基因存在异常表达;P3中未见此异常。
- 数据可将患者按不同基因表达谱分组,并与临床参数对应。
- 功能研究和血小板mRNA表达发现肌动蛋白细胞骨架改变、GFI1B下调、GPVI下游信号缺陷以及α颗粒蛋白(如血小板反应蛋白-1)减少,这些特征可能参与血小板减少和血小板功能障碍。
关键数值与推荐
- P1携带c.802C>T[p.Gln268∗]新发变异,近期发生骨髓增生异常综合征。
- P2携带c.586A>G[p.Thr196Ala]变异,该变异在家族中与血小板减少和髓系肿瘤共分离。
- P3携带c.476A>G[p.Asn159Ser]变异,该变异未与血小板减少或肿瘤共分离。
- 在P1和P2中,转录组分析证实RUNX1靶基因异常表达;P3中未见。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Germline mutations in RUNX1 can cause a familial platelet disorder that may lead to acute myeloid leukemia, an autosomal dominant disorder characterized by moderate thrombocytopenia, platelet dysfunction, and a high risk of developing acute myeloid leukemia or myelodysplastic syndrome. Discerning the pathogenicity of novel RUNX1 variants is critical for patient management. OBJECTIVES: To extend the characterization of RUNX1 variants and evaluate their effects by transcriptome analysis. METHODS: Three unrelated patients with long-standing thrombocytopenia carrying heterozygous RUNX1 variants were included: P1, who is a subject with recent development of myelodysplastic syndrome, with c.802 C>T[p.Gln268∗] de novo; P2 with c.586A>G[p.Thr196Ala], a variant that segregates with thrombocytopenia and myeloid neoplasia in the family; and P3 with c.476A>G[p.Asn159Ser], which did not segregate with thrombocytopenia or neoplasia. Baseline platelet evaluations were performed. Ultrapure platelets were prepared for platelet transcriptome analysis. RESULTS: In P1 and P2, but not in P3, transcriptome analysis confirmed aberrant expression of genes recognized as RUNX1 targets. Data allowed grouping patients by distinct gene expression profiles, which were partitioned with clinical parameters. Functional studies and platelet mRNA expression identified alterations in the actin cytoskeleton, downregulation of GFI1B, defective GPVI downstream signaling, and reduction of alpha granule proteins, such as thrombospondin-1, as features likely implicated in thrombocytopenia and platelet dysfunction. CONCLUSION: Platelet phenotype, familial segregation, and platelet transcriptomics support the pathogenicity of RUNX1 variants p.Gln268∗ and p.Thr196Ala, but not p.Asn159Ser. This study is an additional proof of concept that platelet RNA analysis could be a tool to help classify pathogenic RUNX1 variants and identify novel RUNX1 targets.
引用
- Palma-Barqueros V, Bastida JM, López Andreo MJ, et al. Platelet transcriptome analysis in patients with germline RUNX1 mutations. J Thromb Haemost. 2023. PMID: 36736831. doi:10.1016/j.jtha.2023.01.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。